Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cg Oncology Inc's Business Segments
Cg Oncology Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Member
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
- Commercial and Development Revenue0%
- License and Collaboration Revenue2.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 2 | - |
| Commercial and Development Revenue | $ 2 | - |
| License and Collaboration Revenue | $ 0 | 2.1% |
Revenue by Product & Service Category - FY
- Commercial and Development Revenue98.7%
- License and Collaboration Revenue1.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Commercial and Development Revenue | $ 1 | 98.7% |
| License and Collaboration Revenue | $ 0 | 1.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
- Commercial and Development Revenue0%
- License and Collaboration Revenue2.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 2 | - |
| Commercial and Development Revenue | $ 2 | - |
| License and Collaboration Revenue | $ 0 | 2.1% |
Description of Cg Oncology Inc
The registrant develops therapeutic products, focusing on cretostimogene for high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC) patients. The company is conducting ongoing and planned clinical trials and preclinical studies to assess the safety, efficacy, and therapeutic potential of cretostimogene. It is exploring a two-step administration process that may provide equivalent or improved outcomes compared to the current five-step process. The company's business strategy includes regulatory filings and approvals, commercialization plans, pricing and reimbursement considerations, and the development of future product candidates. Additionally, the company is evaluating strategic collaborations to support its operations and product development. The business involves significant risks and uncertainties that may impact actual results, as outlined in the risk factors section of the report.